News
COLL
35.90
+3.70%
1.28
Weekly Report: what happened at COLL last week (0615-0619)?
Weekly Report · 2d ago
Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?
Simply Wall St · 3d ago
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha · 6d ago
Weekly Report: what happened at COLL last week (0608-0612)?
Weekly Report · 06/15 09:53
Weekly Report: what happened at COLL last week (0601-0605)?
Weekly Report · 06/08 09:50
Collegium Pharmaceutical awards 50,305 RSUs to 34 newly hired employees under inducement plan
PUBT · 06/05 12:00
COLLEGIUM PHARMACEUTICAL REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/05 12:00
Weekly Report: what happened at COLL last week (0525-0529)?
Weekly Report · 06/01 09:53
Collegium Pharma to join Jefferies Global Healthcare Conference fireside chat
PUBT · 05/27 12:04
Weekly Report: what happened at COLL last week (0518-0522)?
Weekly Report · 05/25 09:55
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story
Simply Wall St · 05/21 21:26
Collegium Pharma director John Gordon Freund sells 20 shares for $681
PUBT · 05/20 20:06
Collegium Pharma Leans on ADHD to Drive Growth
TipRanks · 05/20 05:15
Collegium Pharmaceutical Director Cashes In With Notable Insider Stock Sale
TipRanks · 05/19 02:09
Collegium director John Gordon Freund disposes 4,127 shares for $142,557.58
PUBT · 05/18 20:16
Collegium Pharma director Michael Donovan files initial beneficial ownership statement
PUBT · 05/18 20:04
Top 10 small‑cap value picks: lowest forward P/Es and strong profitability
Seeking Alpha · 05/18 10:43
Weekly Report: what happened at COLL last week (0511-0515)?
Weekly Report · 05/18 09:55
Have Collegium Pharmaceutical Insiders Been Selling Stock?
Simply Wall St · 05/17 13:05
Collegium Shareholders Back Board, Pay and Auditor Choices
TipRanks · 05/15 22:14
More
Webull provides a variety of real-time COLL stock news. You can receive the latest news about Collegium Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About COLL
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.